Immunosenescence and comorbidities increase the susceptibility of older adults with diabetes mellitus (DM) to vaccine-preventable diseases, hospitalization, disability, or death. This systematic review synthesizes research on protecting older adults with DM during pandemics, exploring vaccine safety, tolerance, and vaccination uptake by older adults in anticipation of seasonal influenza outbreaks during the current COVID-19 threat. Addressed were: (a) age-related factors influencing the effectiveness of vaccines against infectious disease in older adults; (b) vaccine safety, tolerance, effectiveness for older persons with DM; and (c) issues affecting older adults accepting immunization recommendations. Medline and CINAHL databases yielded 214 studies with 43 meeting inclusion criteria (32 descriptive and 11 controlled trials). Findings show altered glycemic control stimulates proinflammatory mediators, increasing infection risk, vaccines, and annual revaccinations safely reduce hospitalization rates, mortality outcomes, without affecting glycemic control. However, vaccines fail to evoke optimal antibody responses in older adults. Unawareness, fear of side effects, tend to lower vaccination participation.
AchtymichukK. A.JohnsonJ. A.Al SayahF.EurichD. T. (2015). Characteristics and health behaviors of diabetic patients receiving influenza vaccination. Vaccine, 33(30), 3549–3555. https://doi.org/10.4037/ccn2009969
2.
AkmatovM. K.RieseP.TrittelS.MayM.ProkeinJ.IlligT.SchindlerC.GuzmánC. A.PesslerF. (2019). Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly. BioMed Central Infectious Diseases, 19(1), 656. https://doi.org/10.1186/s12879-019-4214-x
3.
AthamnehL. N.SansgiryS. S. (2014). Influenza vaccination in patients with diabetes: Disparities in prevalence between African Americans and Whites. Pharmacy Practice, 12(2), 410–417. https://doi.org/10.4321/s1886-36552014000200008
4.
ByeonK. H.KimJ.ChoiB.ChoiB. Y. (2018). The coverage rates for influenza vaccination and related factors in Korean adults aged 50 and older with chronic disease: Based on 2016 Community Health Survey data. Epidemiology and Health, 40, e2018034. https://doi.org/10.4178/epih.e2018034
5.
Centers for Disease Control and Prevention. (2011). Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 60(50), 1709. Reviewed from https://www-cdc-gov.webproxy2.ouhsc.edu/mmwr/preview/mmwrhtml/mm6050a4.htm
Centers for Disease Control and Prevention. (2016b). Vax view: Vaccination coverage. U.S. Department of Health and Human Services. Reviewed from https://www.cdc.gov/vaccines/vaxview/
8.
ColquhounA.NicholsonK.BothaJ.RaymondN. (1997). Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiology & Infection, 119(3), 335–341. https://doi.org/10.1017/S095026889700825X
9.
DavisT. M.KauhanenJ.DavisW. A. (2017). Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: The Fremantle Diabetes Study Phase II. Internal Medicine Journal, 47(10), 1206–1210. https://doi.org/10.1111/imj.13569
10.
DeSheaL.ToothakerL. E. (2015). Introductory statistics for the health sciences. Boca Raton, FL: Chapman & Hall/CRC.
11.
DieperslootR.BouterK. P.BeyerW.HoekstraJ.MasurelN. (1987). Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia, 30(6), 397–401. http://doi.org/10.1007/bf00292541
12.
Dodd-McCueD.TartagliaA. (2010). Self-report response bias: Learning how to live with its diagnosis in chaplaincy research. Chaplaincy Today, 26(1), 2–8. https://doi.org/10.1080/10999183.2010.10767394
13.
DorrellL.HassanI.ChakravertyP.OngE. (1997). Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. International Journal of STD & AIDS, 8(12), 776–779. https://doi.org/10.1258/0956462971919264
14.
DowerJ.DonaldM.BegumN.VlackS.OzolinsI. (2011). Patterns and determinants of influenza and pneumococcal immunisation among adults with chronic disease living in Queensland, Australia. Vaccine, 29(16), 3031–3037. https://doi.org/10.1016/j.vaccine.2011.01.116
15.
EgawaY.OhfujiS.FukushimaW.YamazakiY.MoriokaT.EmotoM.MaedaK.InabaM.HirotaY. (2014). Immunogenicity of influenza A (H1N1) pdm09 vaccine in patients with diabetes mellitus: With special reference to age, body mass index, and HbA1c. Human Vaccines & Immunotherapeutics, 10(5), 1187–1194. https://doi.org/10.4161/hv.28252
16.
EgedeL. E. (2003). Association between number of physician visits and influenza vaccination coverage among diabetic adults with access to care. Diabetes Care, 26(9), 2562–2567. https://doi.org/10.2337/diacare.26.9.2562
17.
EgedeL. E.ZhengD. (2003a). Racial/ethnic differences in adult vaccination among individuals with diabetes. American Journal of Public Health, 93(2), 324–329. https://doi.org/10.2105/AJPH.93.2.324
18.
EgedeL. E.ZhengD. (2003b). Racial/ethnic differences in influenza vaccination coverage in high-risk adults. American Journal of Public Health, 93(12), 2074–2078. https://doi.org/10.2105/AJPH.93.12.2074
19.
FeeryB. J.HartmanL. J.HampsonA. W.ProiettoJ. (1983). Influenza immunization in adults with diabetes mellitus. Diabetes Care, 6(5), 475–478. https://doi.org/10.2337/diacare.6.5.475
20.
FrascaD.DiazA.RomeroM.MendezN. V.LandinA. M.RyanJ. G.BlombergB. B. (2013). Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine, 31(35), 3603–3610. https://doi.org/10.1016/j.vaccine.2013.05.003
21.
FreedmanM.KrogerA.HunterP.AultK. A. (2020). Recommended adult immunization schedule, United States, 2020. Annals of Internal Medicine, 172(5), 337–347. https://doi.org/10.7326/M20-0046
22.
Gorska-CiebiadaM.Saryusz-WolskaM.CiebiadaM.LobaJ. (2015). Pneumococcal and seasonal influenza vaccination among elderly patients with diabetes. Advances in Hygiene & Experimental Medicine, 69, 1182–1189. https://doi.org/10.5604/17322693.1176772
23.
GostinL. O.SalmonD. A. (2020). The dual epidemics of COVID-19 and influenza: Vaccine acceptance, coverage, and mandates. Journal of the American Medical Association, 324(4), 335–336. https://doi.org/10.1001/jama.2020.10802
24.
HaqK.FulopT.TedderG.GentlemanB.GarneauH.MeneillyG. S.KleppingerA.PawelecG.McElhaneyJ. E. (2017). Cytomegalovirus seropositivity predicts a decline in the T cell but not the antibody response to influenza in vaccinated older adults independent of type 2 diabetes status. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 72(9), 1163–1170. https://doi.org/10.1093/gerona/glw216
25.
HoergerT. J.SchillieS.WittenbornJ. S.BradleyC. L.ZhouF.ByrdK.MurphyT. V. (2013). Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care, 36(1), 63–69. https://doi.org/10.2337/dc12-0759
26.
HuangI.LimM. A.PranataR. (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—A systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), 395–403. https://doi.org/10.1016/j.dsx.2020.04.018
27.
Jimenez-GarciaR.Lopez-de-AndresA.Hernandez-BarreraV.Gomez-CampeloP.San Andres-RebolloF. J.de Burgos-LunarC.Cardenas-ValladolidJ.Abanades-HerranzJ. C.Salinero-FortM. A. (2017). Influenza vaccination in people with type 2 diabetes, coverage, predictors of uptake, and perceptions. Result of the MADIABETES cohort a 7 years follow up study. Vaccine, 35(1), 101–108. https://doi.org/10.1016/j.vaccine.2016.11.039
28.
Jimenez-TrujilloI.Jimenez-GarciaR.Esteban-HernandezJ.Hernandez-BarreraV.Carrasco GarridoP.Salinero-FortM. A.Cardenas-ValladolidJ.Lopez-de-AndresA. (2015). Predictors of adherence to multiple clinical preventive recommendations among adults with diabetes in Spain. PLoS ONE, 10(6), Article e0131844. https://doi.org/10.1371/journal.pone.0131844
29.
Jimenez-TrujilloI.Lopez-de AndresA.Hernandez-BarreraV.Carrasco-GarridoP.Santos-SanchoJ. M.Jimenez-GarciaR. (2013). Influenza vaccination coverage rates among diabetes sufferers, predictors of adherence and time trends from 2003 to 2010 in Spain. Human Vaccines & Immunotherapeutics, 9(6), 1326–1332. https://doi.org/10.4161/hv.23926
30.
JoshiS. R.ShawA. C.QuagliarelloV. J. (2009). Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine. Yale Journal of Biology & Medicine, 82(4), 142–151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794489/
31.
KirkmanM. S.BriscoeV. J.ClarkN.FlorezH.HaasL. B.HalterJ. B.HuangE. S.KorytkowskiM. T.MunshiM. N.OdegardP. S. (2012). Diabetes in older adults. Diabetes Care, 35(12), 2650–2664. https://doi.org/10.2337/dc12-1801
LedermanM. M.SchiffmanG.RodmanH. M. (1981). Pneumococcal immunization in adult diabetics. Diabetes, 30(2), 119–121. https://doi.org/10.2337/diab.30.2.119
34.
Lewis-ParmarH.McCannR. (2002). Achieving national influenza vaccine targets—An investigation of the factors affecting influenza vaccine uptake in older people and people with diabetes. Communicable Disease and Public Health, 5(2), 119–126. https://pubmed.ncbi.nlm.nih.gov/12166297/
35.
Looijmans-Van den AkkerI.VerheijT. J.BuskensE.NicholK. L.RuttenG. E.HakE. (2006). Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care, 29(8), 1771–1776. https://doi.org/10.2337/dc05-2517
36.
MachadoA.KislayaI.SantosA. J.GaioV.GilA. P.BarretoM.NamoradoS.AntunesL.Matias DiasC.NunesB. (2018). Factors associated to repeated influenza vaccination in the Portuguese adults with chronic conditions. Vaccine, 36(35), 5265–5272. https://doi.org/10.1016/j.vaccine.2018.07.041
37.
McElhaneyJ. E.PinkoskiM. J.AuD.LecheltK. E.BleackleyR. C.MeneillyG. S. (1996). Helper and cytotoxic T lymphocyte responses to influenza vaccination in healthy compared to diabetic elderly. Vaccine, 14(6), 539–544. https://doi.org/10.1016/0264-410X(95)00219-Q
38.
NamJ. S.KimA. R.YoonJ. C.ByunY.KimS. A.KimK. R.ChoS.SeongB. L.AhnC. W.LeeJ. M. (2011). The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea. Diabetic Medicine, 28(7), 815–817. https://doi.org/10.1111/j.1464-5491.2011.03255.x
39.
PeraA.CamposC.LópezN.HassounehF.AlonsoC.TarazonaR.SolanaR. (2015). Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas, 82(1), 50–55. https://doi.org/10.1016/j.maturitas.2015.05.004
40.
PetersonM. H.BarnasonS.DonnellyB.HillK.MileyH.RiggsL.WhitemanK. (2014). Choosing the best evidence to guide clinical practice: Application of AACN levels of evidence. Critical Care Nurse, 34(2), 58–68. https://doi.org/10.4037/ccn2014411
41.
PillsburyA. J.FathimaP.QuinnH. E.CashmanP.BlythC. C.LeebA.MacartneyK. K. (2020). Comparative postmarket safety profile of adjuvanted and high-dose influenza vaccines in individuals 65 years or older. Journal of the American Medical Association Network Open, 3(5), e204079–e204079. https://doi.org/10.1001/jamanetworkopen.2020.4079
42.
PozzilliP.GaleE.VisallilN.BaroniM.CrovariP.FrighiV.CavalloM.AndreaniD. (1986). The immune response to influenza vaccination in diabetic patients. Diabetologia, 29(12), 850–854. https://doi.org/10.1007/bf00870139
43.
SantaulariaJ.HouW.PerveenG.WelshE.FaseruB. (2016). Prevalence of influenza vaccination and its association with health conditions and risk factors among Kansas adults in 2013: A cross-sectional study. BioMed Central Public Health, 16, 185. https://doi.org/10.1186/s12889-016-2884-5
44.
SatmanI.AkalinS.CakirB.AltinelS. (2013). The effect of physicians’ awareness on influenza and pneumococcal vaccination rates and correlates of vaccination in patients with diabetes in Turkey: An epidemiological Study “diaVAX”. Human Vaccines & Immunotherapeutics, 9(12), 2618–2626. https://doi.org/10.4161/hv.25826
45.
SchillieS.WesterC.OsborneM.WesolowskiL.RyersonA. B. (2020). CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recommendations and Reports, 69(2), 1. https://doi.org/doi:10.15585/mmwr.rr6902a1
46.
SelvaisP. L.HermansM. P.DonckierJ. E.BuysschaertM. (1997). Reported rates, incentives, and effectiveness of major vaccinations in 501 attendees at two diabetes clinics. Diabetes Care, 20(7), 1212–1213. https://doi.org/10.2337/diacare.20.7.1212
47.
SeñaA. C.MoormanA.NjordL.WilliamsR. E.ColbornJ.KhudyakovY.DrobenuicJ.XiaG. L.WoodH.MooreZ. (2013). Acute hepatitis b outbreaks in 2 skilled nursing facilities and possible sources of transmission: North Carolina, 2009–2010. Infection Control & Hospital Epidemiology, 34(7), 709–716. https://doi.org/10.1086/670996
48.
SeoY. B.BaekJ. H.LeeJ.SongJ. Y.LeeJ. S.CheongH. J.KimW. J. (2015). Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes. Clinical & Vaccine Immunology, 22(11), 1160–1165. https://doi.org/10.1128/CVI.00288-15
49.
ShakeriH.LemmensK.GevaertA. B.De MeyerG. R.SegersV. F. (2018). Cellular senescence links aging and diabetes in cardiovascular disease. American Journal of Physiology-Heart and Circulatory Physiology, 315(3), H448–H462. https://doi.org/10.1152/ajpheart.00287.2018.
50.
SheridanP. A.PaichH. A.HandyJ.KarlssonE. A.HudgensM. G.SammonA. B.HollandL. A.WeirS.NoahT. L.BeckM. A. (2012). Obesity is associated with impaired immune response to influenza vaccination in humans. International Journal of Obesity, 36(8), 1072–1077. https://pubmed.ncbi.nlm.nih.gov/22024641
51.
SheridanP. A.PaichH. A.HandyJ.KarlssonE. A.Schultz-CherryS.HudgensM.WeirS.NoahT.BeckM. A. (2015). The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine, 33(29), 3306–3313. https://doi.org/10.1016/j.vaccine.2015.05.043
ShinH. Y.ChungJ. H.HwangH. J.KimT. H. (2018). Factors influencing on influenza vaccination and its trends of coverage in patients with diabetes in Korea: A population-based cross-sectional study. Vaccine, 36(1), 91–97. https://doi.org/10.1016/j.vaccine.2017.11.035
54.
StewartL. A.ClarkeM.RoversM.RileyR. D.SimmondsM.StewartG.TierneyJ. F. (2015). Preferred reporting items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD statement. Journal of the American Medical Association, 313(16), 1657–1665. https://doi.org/10.1001/jama.2015.3656
55.
VamosE. P.PapeU. J.CurcinV.HarrisM. J.ValabhjiJ.MajeedA.MillettC. (2016). Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. Canadian Medical Association Journal, 188(14), E342–E351. https://doi.org/10.1503/cmaj.151059
56.
Van Der MeerenO.PetersonJ. T.DionneM.BeasleyR.EbelingP. R.FergusonM.NissenM. D.RheaultP.SimpsonR. W.De RidderM. (2016). Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Human Vaccines & Immunotherapeutics, 12(8), 2197–2203. https://doi.org/10.1080/21645515.2016.1164362
57.
VenturaM. T.CasciaroM.GangemiS.BuquicchioR. (2017). Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation. Clinical and Molecular Allergy, 15(1), 21. https://doi.org/10.1186/s12948-017-0077-0
58.
VergerP.CortaredonaS.PulciniC.CasanovaL.Peretti-WatelP.LaunayO. (2015). Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: A follow-up study from 2008 to 2011 in southeastern France. Clinical Microbiology & Infection, 21(10), 930.e931–930.e 939. https://doi.org/10.1016/j.cmi.2015.06.017
59.
Vila-CórcolesA.Ochoa-GondarO.EsterF.SarráN.AnsaX.SaúnN. (2006). Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up. BioMed Central Public Health, 6(1), 231. https://doi.org/10.1186/1471-2458-6-231
60.
Vila-CórcolesA.RodriguezT.de DiegoC.OchoaO.ValdiviesoA.SalsenchE.AnsaX.BadíaW.SaúnN.GroupE. S. (2007). Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002–2005 influenza periods. Vaccine, 25(37–38), 6699–6707. https://doi.org/10.1016/j.vaccine.2007.07.015
61.
VillarroelM. A.VahratianA. (2016). Vaccination coverage among adults with diagnosed diabetes, United States, 2015. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. https://www.cdc.gov/nchs/products/databriefs/db265.htm
62.
VoordouwA.SturkenboomM.DielemanJ.StijnenT.SmithD. J.van der LeiJ.StrickerB. H. C. (2004). Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. Journal of the American Medical Association, 292(17), 2089–2095. https://doi.org/10.1001/jama.292.17.2089
63.
WahidS. T.NagS.BilousR. W.MarshallS. M.RobinsonA. C. (2001). Audit of influenza and pneumococcal vaccination uptake in diabetic patients attending secondary care in the Northern Region. Diabetic Medicine, 18(7), 599–603. https://doi.org/10.1046/j.1464-5491.2001.00549.x
64.
WangI.-K.LinC.-L.ChangY.-C.LinP.-C.LiangC.-C.LiuY.-L.ChangC.-T.YenT.-H.HuangC.-C.SungF.-C. (2013). Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine, 31(4), 718–724. https://doi.org/10.1016/j.vaccine.2012.11.017
65.
YangL.NanH.LiangJ.ChanY. H.ChanL.SumR. W.KwanY. M.ZhouF.MengH.SuenL. K. (2017). Influenza vaccination in older people with diabetes and their household contacts. Vaccine, 35(6), 889–896. https://doi.org/10.1016/j.vaccine.2017.01.004
66.
YuM. C.ChouY. L.LeeP. L.YangY. C.ChenK. T. (2014). Influenza vaccination coverage and factors affecting adherence to influenza vaccination among patients with diabetes in Taiwan. Human Vaccines & Immunotherapeutics, 10(4), 1028–1035. https://doi.org/10.4161/hv.27816
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
